CN105219728A - A kind of for activating the immunoreactive test kit of Breast Cancer-Specific - Google Patents
A kind of for activating the immunoreactive test kit of Breast Cancer-Specific Download PDFInfo
- Publication number
- CN105219728A CN105219728A CN201510685141.6A CN201510685141A CN105219728A CN 105219728 A CN105219728 A CN 105219728A CN 201510685141 A CN201510685141 A CN 201510685141A CN 105219728 A CN105219728 A CN 105219728A
- Authority
- CN
- China
- Prior art keywords
- cell
- test kit
- seqidno
- breast cancer
- supernatant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a kind of for activating the immunoreactive test kit of Breast Cancer-Specific, including the combination of RPMI-1640 substratum, cells and supernatant, GM-CSF, IL-4, INF γ and Breast Cancer-Specific antigenic peptide; Described cells and supernatant is NK cell and K562 co-culture of cells supernatant or T cell culture supernatant; Described Breast Cancer-Specific antigenic peptide is combined as MAGE-A1-A2, MAGE-A1-A3, NY-ESO-1-A2, PLAC1-A2, PIWIL2-A2, CEA-A2, CEA-A3, Mamaglobin-A-A3, NY-BR-1-A2, HER2-A2, HER2-A3 and MTA1-A2; Test kit of the present invention can activate the specific immune response of breast cancer patients in the mode that initiatively induction/passive induction phase combines efficiently.
Description
Technical field
The present invention relates to a kind of test kit strengthening antitumor immune, particularly relating to a kind of for activating the immunoreactive test kit of Breast Cancer-Specific.
Background technology
Female mammary gland is made up of skin, fibrous tissue, corpus mamma and fat, and mammary cancer is the malignant tumour occurring in mammary gland glandular epithelium tissue.In mammary cancer, 99% occurs in women, and the male sex only accounts for 1%.
Mammary gland is not the vitals maintaining human life activity, and breast cancer in situ is not fatal; But because breast cancer cell loses Normocellular characteristic, connect loose between cell, easily come off.Cancer cells is once come off, and free cancer cells can send out whole body with blood or lymph liquid, forms transfer, threat to life.Current mammary cancer has become the able-bodied kinds of tumor of threat women.
Whole world breast cancer incidence starts always in rising trend from late 1970s.The U.S. 8 women just have 1 people in life and suffer from breast cancer.China is not the country occurred frequently of mammary cancer, but unsuitable optimistic, and the rate of growth of China's breast cancer incidence but exceeds national 1 ~ 2 percentage point occurred frequently in recent years.Pathogenesis of breast carcinoma data presentation in 2009 according to National Cancer Center and prevention and control of diseases office of the Ministry of Health are announced for 2012: national tumour registers the 1st that regional breast cancer incidence occupies female malignant, female mammary gland cancer morbidity (rough and careless) whole nation adds up to 42.55/10 ten thousand, city is 51.91/10 ten thousand, and rural area is 23.12/10 ten thousand.
Since entering 21st century, molecular biology and immunologic rapid progress are that clinical cancer therapy provides new strategy.Identified the antigen of a large amount of tumor cell specifics by molecular biological means, and gone out it by the site of immunocyte identification by the means analysis of information biology, this is that the tumor-specific immunity of reconstruction patients reacts the possibility brought.But a series of clinical test results displays since last decade, the clinical effectiveness of the tumor vaccine based on tumour specific antigen peptide is disappointing, and one of them important reason is the defect of angtigen presentation process.
The DC cell of people's slow virus infections such as XiZhao makes the exogenous IL12 of its persistence high expression level, find that DC.IL12 cell can the generation of inducing antigen-specific CTL cell efficiently, DC.IL12 and tumor antigen peptide to be fed back in Mice Body can significance reduce tumor mass.The DC cell infecting unloaded virus can not effectively excite corresponding immune response, on the impact of the tumor size of mouse without significance after feedback.This research has pointed out the DC cell of high expression level IL12 tumor vaccine to be played to the importance of its anticancer clinical effect.
DC cell is a class cell in mammal body with HLA-II antigen, and its major function is picked-up, processing treatment and present antigen, activates or regulates adaptive immune response.Therefore T cell is activated and generates a type t helper cell (type1Thelper, Th1) of MHC-I class restricted CD8 positive cytotoxic T cells (CytotoxicTlymphocyte, CTL) and the restrictive CD4 positive of MHC-II class.One type polarization dendritic cell (Type1PolarizedDendriticcell, DC1) is a class subgroup of ripe DC cell, has strong immuno-stimulating ability.The important feature of DC1 cell is high expression level IL12p70 and immuno-stimulating costimulatory molecules, can activation antigen specific CD8+T cell is relevant with CD4+Th1 cell efficiently immune response.RobbieB.Mailliard etc. confirm that the ability of the external evoked melanoma-associated antigen of DC1 specific CTL cell can reach more than 40 times of normal ripe DC cell.The people such as AdrianaTLarregina also find DC1 cell induction B16 melanoma-associated antigen specific C D4+ helper T cell, and promote that CD4+ helper T cell is to the infiltration of tumor tissues.Therefore, the DC1 cell loading tumour specific antigen peptide of high expression level IL12 can provide a kind of strategy for the oncotherapy curative effect based on enhancement antigen peptide, but also do not have in prior art can be corresponding, ripe and be applicable to activate the test kit of breast cancer patients specific immune response.
Summary of the invention
The present invention solves the aforementioned problems in the prior to propose the clinical treatment of a kind of test kit for mammary cancer.The DC cell that external evoked tumour patient is autologous, obtains the product of enrichment DC1 cell; DC1 cell loading tumour-specific peptide section combines, and may be used for the induction of the cytotoxic T cell of the specific for tumour antigen in external or body.
In order to solve the problems of the technologies described above, technical measures provided by the present invention are:
The invention provides a kind of for activating the immunoreactive test kit of Breast Cancer-Specific, including the combination of RPMI-1640 substratum, cells and supernatant, GM-CSF, IL-4, INF γ and Breast Cancer-Specific antigenic peptide; Wherein, described cells and supernatant is NK cell and K562 co-culture of cells supernatant or T cell culture supernatant; Described Breast Cancer-Specific antigenic peptide is combined as MAGE-A1-A2, MAGE-A1-A3, NY-ESO-1-A2, PLAC1-A2, PIWIL2-A2, CEA-A2, CEA-A3, Mamaglobin-A-A3, NY-BR-1-A2, HER2-A2, HER2-A3, MTA1-A2, its peptide sequence is respectively as SEQIDNo.1, SEQIDNo.2, SEQIDNo.3, SEQIDNo.4, SEQIDNo.5, SEQIDNo.6, SEQIDNo.7, SEQIDNo.8, shown in SEQIDNo.9, SEQIDNo.10, SEQIDNo.11 and SEQIDNo.12.
In order to optimize technique scheme further, the technical measures that the present invention takes also comprise:
Preferably, NK cell and K562 co-culture of cells supernatant by K562 cell and NK cell are added IFN α in 1:2 to 1:10 ratio Dual culture, 24 h before harvest substratum supernatants and obtaining.
Preferably, in the preparation process of described T cell culture supernatant, first separating periphery blood monocytic cell, lymphocyte separation medium sub-argument mononuclearcell, after going out CD8+T cell with CD8 magnetic bead sorting, be seeded in substratum, add CD3CD28Beads, add equivalent substratum after 24h, after 48h, collect T cell culture supernatant.
Preferably, utilize test kit to activate the reaction of breast cancer patients tumor-specific immunity to comprise the following steps:
Step one, be separated the monocyte in patient's peripheral blood, after the of short duration adherent culture of cell, remove suspension cell, add inductor GM-CSF and IL-4 and cultivate two days, cultivate the 3rd day, within the 5th day, change the substratum of half amount, and add the combination of Breast Cancer-Specific antigenic peptide, obtain the ripe DC cell that load has Breast Cancer-Specific antigenic peptide to combine;
Step 2, cultivates induction further two days by ripe DC cell INF γ obtained in described step one and described NK cell and K562 co-culture of cells supernatant, makes described ripe DC cytodifferentiation be DC1 cell;
Step 3, the DC1 cell utilizing step 2 to obtain carries out initiatively induction and/or external passive induction in body.
Preferably, described NK cell derived is in Human Umbilical Cord's blood.
Preferably, described T cell culture supernatant is for utilizing autologous or allogeneic T cells acquisition.
Preferably, initiatively Induction Process feeds back in patient body for the DC1 cell described step 2 obtained in the body in described step 3.
Preferably, the external passive Induction Process in described step 3 is the DC1 cell that described step 2 obtained and T cell mixed culture, and load Breast Cancer-Specific antigenic peptide, then collecting cell again, feed back in patient body.
Preferably, test kit can also comprise GGT551 substratum, DMEM/F12 substratum or DMEM substratum.
The present invention adopts technique scheme, and compared with prior art, technique effect of the present invention is embodied in the following aspects:
First, the invention provides one group of specific antigens polypeptides in combination for Breast cancer immunotherapy, this combination contains the peptide section of the specific expressed antigen of 12 kinds of breast cancer cells.These peptide sections include the sequence area that HLA-A2 and A3 presents, and cover the mammary tumor cells specific antigen reported of more than 80%.Therefore, we provide the combination of a kind of new Breast Cancer-Specific antigenic peptide, be conducive to activating the acquired immune response for tumour cell suffering from Patients With Carcinoma of Esophagus.
Secondly, present invention also offers one and utilize test kit of the present invention, the ripe DC1 cell of external preparation, for the method for load mammary tumor cells specific antigen combination.Compared with conventional induction scheme, the DC cell content significance having ripe phenotype in the product prepared by test kit of the present invention is utilized to improve (as surface antigen high expression levels such as CD80, CD86, CD40L); After sCD40L stimulates, DC1 cell IL12P70 expression amount is much higher than the expression amount that general scheme prepares cell.As can be seen here, the invention provides more effective ripe DC1 cell and prepare scheme, gained cellular products may be used for mammary tumor cells specific antigen load.
Finally, the invention provides a kind of clinical application protocol of the DC1 Loading peptides for breast cancer treatment.After DC1 cell loading tumour specific antigen, part cell is fed back in patient body, another part is used for the inducing cytotoxic T cell (CTL) of Vitro Tumor antigen-specific, by in body/external, the mode that initiatively induction/passive induction phase combines activates the specific immune response of breast cancer patients.
Accompanying drawing explanation
Compared with the ripe DC cell that Fig. 1 is prepared for DC1 cell and the conventional scheme utilizing test kit of the present invention (cells and supernatant is NK cell and K562 co-culture of cells supernatant) and prepare, CCR7, CD70, HLA-DR, the marker expression amount situation that the DC cells such as CD83, CD86 are relevant to immuno-stimulating;
Compared with Fig. 2 contrast DC cell that to be the DC1 cell T cell culture supernatant of 40% ratio (10% with) prepared of test kit of the present invention (cells and supernatant is T cell culture supernatant) prepare with conventional scheme, CD11C, CD70, HLA-DR, the marker expression amount situation that the DC cells such as CD83, CD86 are relevant to immuno-stimulating;
Fig. 3 is after sCD40L activates, the contrast of the IL-12 secreted by DC1 cell prepared by test kit of the present invention (cells and supernatant is NK cell and K562 co-culture of cells supernatant) and ripe DC emiocytosis amount prepared by conventional scheme;
Fig. 4 is after sCD40L activates, the contrast of the IL-12 secreted by DC1 cell (the T cell culture supernatant of 10% and 40% ratio) prepared by test kit of the present invention (cells and supernatant is T cell culture supernatant) and ripe DC emiocytosis amount prepared by conventional scheme;
After Fig. 5 is the DC1 cell induction T cell prepared of test kit of the present invention (cells and supernatant is NK cell and K562 co-culture of cells supernatant), the contrast of DC cell induction prepared by IFN γ secretion level and common approach in ELIspot test;
After Fig. 6 is DC1 cell (the T cell supernatant of the 10% and 40% ratio) inducing T cell prepared of test kit of the present invention (cells and supernatant is T cell culture supernatant), the contrast of DC cell induction prepared by IFN γ secretion level and common approach in ELIspot test.
Embodiment
The invention provides a kind of for activating the immunoreactive test kit of Breast Cancer-Specific, including the combination of RPMI-1640 substratum, cells and supernatant, GM-CSF, IL-4, INF γ and Breast Cancer-Specific antigenic peptide; Wherein, described cells and supernatant is NK cell and K562 co-culture of cells supernatant or T cell culture supernatant; Described Breast Cancer-Specific antigenic peptide is combined as MAGE-A1-A2, MAGE-A1-A3, NY-ESO-1-A2, PLAC1-A2, PIWIL2-A2, CEA-A2, CEA-A3, Mamaglobin-A-A3, NY-BR-1-A2, HER2-A2, HER2-A3, MTA1-A2, its peptide sequence is respectively as SEQIDNo.1, SEQIDNo.2, SEQIDNo.3, SEQIDNo.4, SEQIDNo.5, SEQIDNo.6, SEQIDNo.7, SEQIDNo.8, shown in SEQIDNo.9, SEQIDNo.10, SEQIDNo.11 and SEQIDNo.12.
Carry out detailed and concrete introduction below by specific embodiment to the present invention, to make better to understand the present invention, but following embodiment does not limit the scope of the invention.
Embodiment one (cells and supernatant is T cell culture supernatant)
When utilizing test kit of the present invention to activate breast cancer patients specific immune response, first carry out the preparation (type1polarizeddendriticcell, DC1) of a type polarization dendritic cell in adult peripheral blood source.Peripheral blood mononuclear cell is separated with reference to the method according to (GeneTher.200310 (3)) such as Jonuleit.First with by Ficoll-Hypaque density gradient centrifugation separating peripheral blood mononuclear cells, and blood plasma is collected for follow-up cultivation.By density 3.0 × 10
6/ ml, is seeded to cell in T75 culturing bottle, and adds 10% blood plasma in GGT551 substratum, be placed in 37.0 DEG C, saturated humidity, 5%CO
2cultivate in environment.After cultivating 3h, wash away the lymphocyte of suspension, add the DMEM/F12 substratum containing GM-CSF and IL-41000IU/ml and 10% blood plasma.Attached cell cultivates the 3rd day, within the 5th day, changes the substratum of half amount.After within 5th day, half amount changes liquid, add T cell supernatant 10%.As shown in Figure 2, through the induction of 6 days, prepare the phenotype that product shows obvious DC cell, the mark relevant to immuno-stimulating such as Flow cytometry result display CD83, CD86 etc. reaches more than 95%, illustrates that to prepare DC cell purity in product high.Also can be found out by Fig. 4, DC1 cell is after sCD40L stimulates, and high expression level IL12, the IL12 amount of the DC cell expressing prepared by test kit of the present invention is approximately 10 times (10%T-DC) of conventional scheme.In detection experiment, within the 5th day, add 10% or the induction of 40%T cell conditioned medium, the DC1 cell of acquisition through sCD40L activate after with T cell Dual culture.ELIspot test (Fig. 6) shows the quantity of quantity higher than common DC cell induction that IFN γ expresses positive T cell.
Be cultured to the 6th day collecting cell and be DC1 cell.DC1 cell cultures was to the 6th day, by centrifugal for the tumor antigen peptide section pulvis of 12 in test kit rear (300g, 10min), often prop up and be dissolved in (each peptide 2ug/ml) in 200ulDMEM/F12 substratum respectively, join after abundant mixing in DC1, hatch 2h.The DC1 cell collected is divided into two parts, every part at least 10
6individual cell, may be used for directly mixing with peptide feeding back in patient body, or for external evoked CTL cell.During DC1 cells in vitro induced tumor Peptide-specific CTL cell, as aforesaid method separating periphery blood monocytic cell, of short duration cultivation in adherent culture ware, the cell that separation can be adherent.Suspension cell is by density 3.0 × 10
6/ ml inoculation culture.Multiple proportions adds RPMI1640 substratum every three days.To cultivating the 5th day and the 6th day, adding respectively to add and activating each 1ml of reagent IFN-γ, CD3 and IL1-α mixed solution.By the antigen peptide load DC1 of acquisition and T cell mixed culture.Multiple proportions adds RPMI1640 substratum every three days.Mixed culture starts latter 4th day, load Breast Cancer-Specific antigen peptide again.By centrifugal for the tumor antigen peptide pulvis in test kit rear (300g, 10min), often pipe adds the GGT551 substratum of 1ml respectively, after fully dissolving mixing, adds in culture system.Afterwards, continue to be cultured to feedback, T cell Time in Vitro should more than 18 days.
The clinical application of the DC1 cell that test kit of the present invention (cells and supernatant is T cell culture supernatant) is induced:
The method of application foregoing description, the present invention is directed to breast cancer patients to have employed DC1 mediated immunity therapy and carry out methods for the treatment of and be summarized as follows: met patient's (III or IV level) of inclusion criteria before carrying out chemotherapy, get peripheral blood 150ml, be prepared the CTL cell of DC1 and specific for tumour antigen by above-mentioned method.
6th day 5-10 × 10 at the lymph node injection antigen load of patient
6individual DC1 cell (being resuspended in 1ml physiological saline), cultivate the 16,17,18 day every day collected 10
9individual DC and T cell Dual culture product, after resuspended in physiological saline, venous re-transfusion.Completed 4 examples at present, just in follow-up observation, not yet find obvious complication, proved method safety is reliable.
Embodiment two (cells and supernatant is NK cell and K562 co-culture of cells supernatant)
Peripheral blood mononuclear cell is separated with reference to the method according to (GeneTher.200310 (3)) such as Jonuleit.First with by Ficoll-Hypaque density gradient centrifugation separating peripheral blood mononuclear cells, and blood plasma is collected for follow-up cultivation.Add IL-2 (2000U/ml) and IL15 (2ng/ml).Within every two to three days, multiple proportions adds substratum, and equivalent SF.Collected to the 12 day.After having induced, NK cell presses 1-3 × 10
6/ ml is seeded in substratum RPMI1640, adds IFNa (1000UI/ml) and with 0.5-1.5 × 10
5/ ml density inoculation K562 cell (can be replaced K562-NK cell) mixed culture, collects the substratum supernatant activated in 24-48 hours period, and after filtration ,-80 degree are frozen or be directly used in the preparation of DC1 cell.Peripheral blood mononuclear cell is by density 3.0 × 10
6/ ml, is seeded to cell in T75 culturing bottle, and containing adding 10% blood plasma in 1000U/mlIL-2 amplification culture medium, be placed in 37.0 DEG C, saturated humidity, 5%CO
2cultivate in environment.After cultivating 3h, wash away the lymphocyte of suspension, add the substratum containing GM-CSF and IL-41000U/ml and 10% blood plasma.Attached cell cultivates the 3rd day, within the 5th day, changes the substratum of half amount.Cultivate the 6th day, change containing 5% plasma medium and add NK cell conditioned medium 10%, and adding IFN γ according to final concentration 1000UI/ml, cultivate the poly-I:C that 20 hours add 20ug/ml afterwards again.Be cultured to the 7th day collecting cell and be DC1 cell.DC1s cell cultures was to the 6th day, by centrifugal for kind of the breast cancer antigen peptide section pulvis of 12 in CTL-TP test kit rear (300g, 10min), often prop up and be dissolved in (each peptide 2ug/ml) in 200ul substratum respectively, join after abundant mixing in DC1, hatch 2h.The DC1 cell collected is divided into two parts, every part at least 10
6individual cell, may be used for directly mixing with peptide feeding back in patient body, or for external evoked CTL cell.
As aforesaid method separating periphery blood monocytic cell, of short duration cultivation in adherent culture ware, the cell that separation can be adherent.Suspension cell is by density 3.0 × 10
6/ ml inoculation culture.Multiple proportions adds the amplification culture medium containing 1000U/mlIL-2 every three days.Adding IFN-γ to cultivating the 5th day, within the 6th day, adding IL-1 α and CD3.
By the antigen peptide load DC1 of above-mentioned acquisition and T cell mixed culture.Multiple proportions adds the amplification culture medium containing 1000U/ml every three days.Mixed culture starts latter 4th day, load Breast Cancer-Specific antigen peptide again.By centrifugal for the tumor antigen peptide pulvis in CTL-TP test kit rear (300g, 10min), often pipe adds the substratum of 1ml respectively, after fully dissolving mixing, adds in culture system.Afterwards, continue to be cultured to feedback, T cell Time in Vitro should more than 20 days.
As shown in Figure 1, through induction, compared with ripe DC cell prepared by the DC1 cell prepared of test kit of the present invention and conventional scheme, multiple surface markers of the mark that the DC cells such as CCR7, CD70, HLA-DR, CD83, CD86 are relevant to immuno-stimulating become the positives.Also can be found out by Fig. 3, the cellular products IL12p70 expression amount that the present invention prepares and obtains is much higher than scheme conventional at present, and the IL-12 secreted by DC1 cell of the present invention's induction is almost 10 times of ripe DC emiocytosis amount prepared by conventional scheme.In detection experiment, external evoked experiment display is after DC1 induction prepared by this test kit, and the T cell of activation and IFN γ express positive T cell significance and raise (Fig. 5).
The clinical application of the DC1 cell that test kit of the present invention (cells and supernatant is T cell culture supernatant) is induced:
The method of application foregoing description, the present invention is directed to breast cancer patients to have employed DC1 mediated immunity therapy and carry out methods for the treatment of and be summarized as follows: met patient's (III or IV level) of inclusion criteria before carrying out chemotherapy, get peripheral blood 150ml, be prepared the CTL cell of DC1 and specific for tumour antigen by above-mentioned method.
7th day 5-10 × 10 at the lymph node injection antigen load of patient
6individual DC1 cell (being resuspended in 1ml physiological saline), cultivate the 16,17,18 day every day collected 10
9individual DC and T cell Dual culture product, after resuspended in physiological saline, venous re-transfusion.Completed 7 examples at present, just in follow-up observation, not yet find obvious complication, proved method safety is reliable.
One of the present invention, for activating the immunoreactive test kit of Breast Cancer-Specific, has the following advantages relative to prior art tool:
First, the invention provides one group of specific antigens polypeptides in combination for Breast cancer immunotherapy, this combination contains the peptide section of the specific expressed antigen of 12 kinds of breast cancer cells.These peptide sections include the sequence area that HLA-A2 and A3 presents, and cover the mammary tumor cells specific antigen reported of more than 80%.Therefore, we provide the combination of a kind of new Breast Cancer-Specific antigenic peptide, be conducive to the acquired immune response for tumour cell activating suffers from breast patient.
Secondly, present invention also offers one and utilize kit box of the present invention to prepare ripe DC1 cell outward, for the method for load mammary tumor cells specific antigen combination.Compared with conventional induction scheme, the DC cell content significance having ripe phenotype in the product prepared by test kit of the present invention is utilized to improve (as surface antigen high expression levels such as CD80, CD86, CD40L); After sCD40L stimulates, DC1 cell IL12P70 expression amount is much higher than the expression amount that general scheme prepares cell.As can be seen here, the invention provides more effective ripe DC1 cell and prepare scheme, gained cellular products may be used for mammary tumor cells specific antigen load.
Finally, the invention provides a kind of clinical application protocol of the DC1 Loading peptides for breast cancer treatment.After DC1 cell loading Breast Cancer-Specific antigen, part cell is fed back in patient body, another part is used for the inducing cytotoxic T cell (CTL) of Vitro Tumor antigen-specific, by in body/external, the mode that initiatively induction/passive induction phase combines activates the specific immune response of patient with breast cancer.
Be described in detail specific embodiments of the invention above, but it is just as example, the present invention is not restricted to specific embodiment described above.To those skilled in the art, any equivalent modifications that the present invention is carried out and substituting also all among category of the present invention.Therefore, equalization conversion done without departing from the spirit and scope of the invention and amendment, all should contain within the scope of the invention.
Claims (9)
1. for activating the immunoreactive test kit of Breast Cancer-Specific, it is characterized in that, including the combination of RPMI-1640 substratum, cells and supernatant, GM-CSF, IL-4, INF γ and Breast Cancer-Specific antigenic peptide; Wherein, described cells and supernatant is NK cell and K562 co-culture of cells supernatant or T cell culture supernatant; Described Breast Cancer-Specific antigenic peptide is combined as sequence as SEQIDNo.1, SEQIDNo.2, SEQIDNo.3, SEQIDNo.4, SEQIDNo.5, SEQIDNo.6, SEQIDNo.7, SEQIDNo.8, the polypeptides in combination of SEQIDNo.9, SEQIDNo.10, SEQIDNo.11 and SEQIDNo.12.
2. test kit according to claim 1, is characterized in that, described NK cell and K562 co-culture of cells supernatant by K562 cell and NK cell are added IFN α in 1:2 to 1:10 ratio Dual culture, 24 h before harvest substratum supernatants and obtaining.
3. test kit according to claim 1, it is characterized in that, in the preparation process of described T cell culture supernatant, first separating periphery blood monocytic cell, lymphocyte separation medium sub-argument mononuclearcell, after going out CD8+T cell with CD8 magnetic bead sorting, be seeded in substratum, add CD3CD28Beads, after 24h, add equivalent substratum, after 48h, collect T cell culture supernatant.
4. test kit according to claim 1, is characterized in that, utilizes test kit to activate the reaction of breast cancer patients tumor-specific immunity and comprises the following steps:
Step one, be separated the monocyte in patient's peripheral blood, after the of short duration adherent culture of cell, remove suspension cell, add inductor GM-CSF and IL-4 and cultivate two days, cultivate the 3rd day, within the 5th day, change the substratum of half amount, and add the combination of Breast Cancer-Specific antigenic peptide, obtain the ripe DC cell that load has Breast Cancer-Specific antigenic peptide to combine;
Step 2, cultivates induction further two days by ripe DC cell INF γ obtained in described step one and described NK cell and K562 co-culture of cells supernatant, makes described ripe DC cytodifferentiation be DC1 cell;
Step 3, the DC1 cell utilizing step 2 to obtain carries out initiatively induction and/or external passive induction in body.
5. test kit according to claim 1 and 2, is characterized in that, described NK cell derived is in Human Umbilical Cord's blood.
6. the test kit according to claim 1 or 3, is characterized in that, described T cell culture supernatant is for utilizing autologous or allogeneic T cells acquisition.
7. test kit according to claim 4, is characterized in that, initiatively Induction Process feeds back in patient body for the DC1 cell described step 2 obtained in the body in described step 3.
8. test kit according to claim 4, it is characterized in that, the external passive Induction Process in described step 3 is the DC1 cell that described step 2 obtained and T cell mixed culture, and load Breast Cancer-Specific antigenic peptide again, then collecting cell, feeds back in patient body.
9. test kit according to claim 1, is characterized in that, also includes GGT551 substratum, DMEM/F12 substratum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510685141.6A CN105219728A (en) | 2015-10-20 | 2015-10-20 | A kind of for activating the immunoreactive test kit of Breast Cancer-Specific |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510685141.6A CN105219728A (en) | 2015-10-20 | 2015-10-20 | A kind of for activating the immunoreactive test kit of Breast Cancer-Specific |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105219728A true CN105219728A (en) | 2016-01-06 |
Family
ID=54988999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510685141.6A Pending CN105219728A (en) | 2015-10-20 | 2015-10-20 | A kind of for activating the immunoreactive test kit of Breast Cancer-Specific |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105219728A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112213488A (en) * | 2018-11-21 | 2021-01-12 | 上海易范科生物科技有限公司 | Application of PL2L60 protein in preparation of kit for early screening or diagnosis of tumor |
| CN113621023A (en) * | 2020-03-18 | 2021-11-09 | 北京鼎成肽源生物技术有限公司 | Breast cancer target antigen, CTL cell cultured by breast cancer target antigen stimulation and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1541113A (en) * | 2001-04-27 | 2004-10-27 | �Ƹ��� | Maturation of antigen-presenting cells using activated T cells |
| CN102822332A (en) * | 2009-12-04 | 2012-12-12 | 干细胞及再生医学国际股份有限公司 | Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts |
-
2015
- 2015-10-20 CN CN201510685141.6A patent/CN105219728A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1541113A (en) * | 2001-04-27 | 2004-10-27 | �Ƹ��� | Maturation of antigen-presenting cells using activated T cells |
| CN102822332A (en) * | 2009-12-04 | 2012-12-12 | 干细胞及再生医学国际股份有限公司 | Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts |
Non-Patent Citations (3)
| Title |
|---|
| JEFFREY L. WONG等: "Helper Activity of NK Cells during the Dendritic Cell-mediated Induction of Melanoma-specific Cytotoxic T Cells", 《J IMMUNOTHER.》 * |
| PAWEL KALINSKI等: "Helper role of NK cells during the induction of anticancer responses by dendritic cells", 《MOLECULAR IMMUNOLOGY》 * |
| 李伟等: "DC-CTL 体外杀伤人胰腺癌细胞效应研究", 《北京师范大学学报》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112213488A (en) * | 2018-11-21 | 2021-01-12 | 上海易范科生物科技有限公司 | Application of PL2L60 protein in preparation of kit for early screening or diagnosis of tumor |
| CN113621023A (en) * | 2020-03-18 | 2021-11-09 | 北京鼎成肽源生物技术有限公司 | Breast cancer target antigen, CTL cell cultured by breast cancer target antigen stimulation and application thereof |
| CN113621024A (en) * | 2020-03-18 | 2021-11-09 | 北京鼎成肽源生物技术有限公司 | Breast cancer target antigen, CTL cell cultured by breast cancer target antigen stimulation and application thereof |
| CN113621025A (en) * | 2020-03-18 | 2021-11-09 | 北京鼎成肽源生物技术有限公司 | Breast cancer target antigen, CTL cell cultured by breast cancer target antigen stimulation and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103756963B (en) | A kind of method of amplification in vitro NK cell | |
| CN108220239B (en) | A kind of stimulation induction mononuclearcell amplification is composition and its application of gamma delta T cells | |
| CN107541498A (en) | A kind of preparation method and its usage of the CD8+T Memorability stem cells of tcr gene modification | |
| CN102597222A (en) | Method for proliferation of antigen-specific T cells | |
| CN105985931A (en) | NK cell in-vitro amplification composition and NK cell amplification method | |
| CN105238754A (en) | Method for in vitro culture of high-proliferation and high-mortality NK cells | |
| CN105176927A (en) | Preparation method of cytotoxicity-enhanced efficient target killing NK/CIK (Natural Killer)/( Cytokine Induced Killer) cells | |
| CN105087488A (en) | Preparation method and application of DC-CIK cell induced by tumor antigen | |
| CN106581668B (en) | Antigen epitope peptide composition and application thereof | |
| CN112980787B (en) | Immune cell preparation for specifically killing tumor cells and preparation method and application thereof | |
| CN110564683A (en) | Method for co-culture induced amplification of gamma delta T cells and NK cells | |
| CN102719402B (en) | Preparation method of HLA-A0201-restricted anti-HPV (human papillomavirus) antigen-specific CTL | |
| CN105802908B (en) | Method for in vitro preparation of tumor antigen specific CD8+ stem cell-like memory T lymphocytes | |
| CN102861107B (en) | DC-CIK (dendritic cells-cytokine-induced killers) cell treatment composition | |
| CN109957543A (en) | Utilize the method for Cord blood massive amplification Cord Blood Natural Killer Cells: Impact | |
| CN105219713A (en) | For high proliferation power, the High Fragmentation power NK cell of tumour adoptive immunity | |
| CN105219728A (en) | A kind of for activating the immunoreactive test kit of Breast Cancer-Specific | |
| CN108642013A (en) | From being detached in Cord blood after CD34 candidate stem cells expand culture, induction prepares Dendritic Cells method to one kind on a large scale | |
| Delirezh et al. | Generation of mature monocyte-derived dendritic cells in the presence of heparin and monocyte conditioned medium: phenotypic and functional comparison | |
| CN105219727A (en) | A kind of test kit for activating colorectal cancer specific immune response | |
| CN105219723A (en) | A kind of test kit for activating cancer of the stomach specific immune response | |
| CN105031631A (en) | Preparation method and application of HLA-A0201-restrictive anti-Sox2 specific CTL | |
| CN103074299B (en) | Method for external induction of tolerogenic dendritic cells (DC) by immunosuppressor | |
| CN105219714A (en) | A kind of test kit for activating lung cancer specific immune response | |
| CN105219715A (en) | A kind of test kit for activating esophageal carcinoma specific immune response |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160106 |